GLP-1 Drugs Raised Severe Gut-Motility Risk by 37%. The Absolute Risk Stayed Low.

The headline number is easy to make frightening: people starting GLP-1-based therapy had a 37% higher relative risk of a serious gastrointestinal motility event than people starting an SGLT-2 inhibitor. The useful number is less dramatic. The difference was 0.27 events per 100 person-years, and the study authors put the absolute risk at 1% or less.

Both facts matter. A new study of more than 626,000 matched adults gives clinicians a clearer signal that severe constipation, gastroparesis, and intestinal obstruction deserve attention. It does not show that these events are common, that every episode was caused by the medication, or that people doing well on treatment should panic and stop.

The new data

Published in Diabetes, Obesity and Metabolism, the study compared adults with type 2 diabetes who newly started a GLP-1-based therapy with adults who newly started an SGLT-2 inhibitor. The GLP-1 group included receptor agonists and tirzepatide. Researchers used two large US commercial healthcare databases, excluded people with a prior major gastrointestinal condition, and matched 313,342 pairs to make the groups more comparable.

The average age was 60 and 45% of participants were women. Median on-treatment follow-up was only 5.2 months. The primary outcome combined three diagnoses: severe constipation, gastroparesis, and gastrointestinal obstruction.

The event rate was 1.02 per 100 person-years in the GLP-1 group and 0.75 per 100 person-years in the SGLT-2 group. That produced a rate difference of 0.27 per 100 person-years and a hazard ratio of 1.37, with a 95% confidence interval from 1.30 to 1.45. In plain language, the GLP-1 group had a statistically clear increase in relative risk, but the excess number of events was small: roughly 2.7 additional composite events per 1,000 person-years under the conditions of this study.

The association was reported for the composite and for each component. It also remained broadly consistent when the researchers divided participants by agent, age, sex, body mass index, frailty, diabetes severity, and opioid use. That consistency makes the signal harder to dismiss as a quirk of one subgroup.

It still does not turn an observational association into proof of causation.

Why the gut is part of the mechanism

GLP-1 therapies do more than influence appetite in the brain. They also slow gastric emptying and change gastrointestinal motility. Early fullness, nausea, vomiting, diarrhea, and constipation are familiar consequences, especially during dose escalation. For many people, these effects are mild or moderate and improve as the body adapts.

A 2026 review by Nimet Yılmaz and Mehmet Bastemir describes that usual pattern, while also noting reports of delayed gastric emptying, gastroparesis-like symptoms, and intestinal obstruction. Its conclusion is appropriately restrained: serious complications appear rare, and the evidence across trials, observational studies, and safety-reporting systems remains inconsistent.

The FDA label for Wegovy is more practical than sensational. It says semaglutide delays gastric emptying, warns that gastrointestinal reactions can sometimes be severe, and states that Wegovy is not recommended in patients with severe gastroparesis. It also tells patients to contact a clinician for severe or persistent gastrointestinal symptoms.

That label language and the new cohort point in the same direction. The mechanism is plausible, and a large real-world dataset now detects a small excess of clinically serious events. Neither source says severe motility injury is the expected outcome.

Relative risk is not absolute risk

A 37% increase sounds enormous when the baseline event is left out. Here, the rate moved from 0.75 to 1.02 events per 100 person-years. The relative comparison can help researchers decide whether a safety signal is likely to be real. The absolute difference helps patients and clinicians judge its size.

The person-year rate is not the same as saying 1.02% of every user will have an event in a calendar year. Follow-up time differs between participants, the median observation period was 5.2 months, and the calculation assumes events accumulate over observed time. It is best read as a standardized rate for comparing groups, not a personal forecast.

The comparison drug matters too. SGLT-2 inhibitors are active diabetes treatments, not placebo. People prescribed one class may differ from people prescribed the other in ways that billing records cannot fully capture. Propensity-score matching can balance measured characteristics. It cannot balance a factor that was not recorded, was poorly coded, or influenced the prescribing decision in a subtle way.

There is another reason for restraint. A 2025 meta-analysis in Gastroenterology pooled 55 placebo-controlled randomized trials with 106,395 participants. It found higher risks of gallstones and probably reflux, but little or no effect on the other gastrointestinal and biliary outcomes it assessed. Randomized trials reduce confounding, but they are often too short or too small to detect very rare harms. Real-world cohorts can detect rarer events, but they are more vulnerable to bias. The disagreement is not a failure of science. It is what different study designs reveal about different parts of the problem.

What the study cannot tell us

The composite endpoint combines three distinct conditions. Severe constipation, gastroparesis, and obstruction do not have identical causes, severity, diagnostic pathways, or treatment. A class-level association also does not establish that semaglutide, tirzepatide, and every other included agent carry the same risk at every dose.

Diagnosis codes are imperfect. Someone taking a GLP-1 drug may be monitored more closely for digestive symptoms because those effects are already well known. That can increase the chance of receiving a diagnosis compared with someone taking a drug class not associated with delayed gastric emptying.

The cohort consisted of adults with type 2 diabetes and no recorded history of a major gastrointestinal condition. Diabetes itself can affect autonomic nerves and gut motility. These results should not be copied directly onto a younger non-diabetic obesity population, nor onto someone with known gastroparesis, prior obstruction, or complex gastrointestinal disease.

The short follow-up creates a final gap. The study is useful for early and near-term risk after initiation. It says much less about people who have tolerated a stable dose for years.

What this means in practice

This paper supports screening and communication, not blanket avoidance. Before treatment, a clinician should know about prior gastroparesis, bowel obstruction, severe chronic constipation, abdominal surgery, neurologic or autonomic disease, and other medicines that slow motility. The FDA already says Wegovy is not recommended for severe gastroparesis.

During treatment, dose escalation is a moment to pay attention. Ordinary nausea or constipation is not automatically a medical emergency, but severe or persistent symptoms should not be normalized as the price of weight loss. Repeated vomiting, inability to keep fluids down, marked abdominal distension, escalating pain, inability to pass stool or gas, or symptoms of dehydration warrant prompt medical assessment. Sudden severe symptoms may require urgent care.

People should not stop a prescribed GLP-1 medicine solely because they read a risk headline. Abrupt decisions can destabilize glucose control, disrupt other treatment goals, and create their own problems. A clinician can assess symptom severity, hydration, dose timing, escalation speed, interacting medicines, and whether treatment should be paused, reduced, switched, or investigated.

The new evidence also argues against a casual culture of aggressive titration. More drug is not automatically better if gastrointestinal tolerability is deteriorating. A slower schedule may be appropriate for some patients, but any dosing change belongs with the prescriber rather than a social-media protocol.

The Oria take

The honest interpretation sits between two bad headlines. “GLP-1 drugs cause stomach paralysis” overstates what an observational study can prove and hides how uncommon the measured events were. “The risk is under 1%, so ignore it” misses a credible signal found in an unusually large active-comparator cohort.

The better takeaway is simple: the risk appears small, not imaginary. For most appropriately selected patients, the cardiovascular, metabolic, and weight-management benefits may still outweigh it by a wide margin. For someone with severe gastroparesis or emerging obstruction symptoms, the same average benefit-risk calculation may no longer apply.

That is how safety evidence should change practice. Not through panic, and not through dismissal, but through better screening, slower decisions when symptoms appear, and a clearer threshold for investigation.

Sources

Alkabbani W, et al. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes Obesity and Metabolism. 2026. https://pubmed.ncbi.nlm.nih.gov/42244136/

Chiang C-H, et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025. https://pubmed.ncbi.nlm.nih.gov/40499738/

Yılmaz N, Bastemir M. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists. 2026. https://pubmed.ncbi.nlm.nih.gov/41884101/

Ismaiel A, et al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity. International Journal of Obesity. 2025. https://pubmed.ncbi.nlm.nih.gov/40804463/

US Food and Drug Administration. Wegovy prescribing information, revised February 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf

Evidence grade: B. A very large, well-designed active-comparator cohort produced a precise and biologically plausible safety signal, but the evidence remains observational, follow-up was short, and randomized-trial meta-analysis has not confirmed a broad increase in rare severe motility events.

Medical disclaimer: This article is for educational purposes only and is not medical advice. GLP-1 medicines are prescription treatments with individual benefits and risks. Do not start, stop, or change a medication or dose without a qualified healthcare professional. Seek urgent medical care for severe abdominal pain, persistent vomiting, marked swelling, inability to pass stool or gas, or signs of dehydration.